Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
Launched by BOSTON SCIENTIFIC CORPORATION · Jul 24, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET) is a clinical trial aimed at understanding how well a specific medical device, called Deep Brain Stimulation (DBS) Systems, works in real-life situations for people with essential tremor. Essential tremor is a condition that causes uncontrollable shaking, which can affect daily activities. This study is currently looking for participants who are at least 18 years old and meet specific criteria related to their condition.
If you or someone you know is interested in joining this trial, you should know that all genders are welcome, and the study is focused on gathering information about the effectiveness of the DBS Systems when used as directed. Participants will share their experiences and outcomes, helping researchers learn more about this treatment option. If you have any medical conditions that would prevent you from using the device, you may not be eligible. This study is a chance to contribute to important research that could improve treatment for essential tremor.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meets criteria established in the locally applicable Directions for Use (DFU) for Essential Tremor
- • Is at least 18 years old
- Exclusion Criteria:
- • Meets any contraindication in locally applicable Directions for Use
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Seoul, , Korea, Republic Of
Leuven, , Belgium
Gent, , Belgium
Seoul, , Korea, Republic Of
Essen, , Germany
Seoul, , Korea, Republic Of
Rome, , Italy
Würzburg, , Germany
Roeselare, , Belgium
Düsseldorf, , Germany
Kiel, , Germany
Marburg, , Germany
Oldenburg, , Germany
Pécs, , Hungary
Oviedo, , Spain
Vancouver, , Canada
Cologne, , Germany
Porto, , Portugal
Barcelona, , Spain
Patients applied
Trial Officials
Natalie Bloom Lyons
Study Director
Boston Scientific Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials